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The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) conducts large, multi-institutional
clinical trials with the goal of improving the outcomes of hematopoietic cell transplantation (HCT) for pa-
tients with life-threatening disorders. Well-designed HCT trials beneﬁt from standardized criteria for deﬁning
diagnoses, treatment plans, and graft source selection. In this perspective, we summarize evidence sup-
porting criteria for the selection of related and unrelated adult volunteer progenitor cell donors or umbilical
cord blood units. These standardized criteria for graft source selection have been adopted by the BMT CTN to
enhance the interpretation of clinical ﬁndings within and among future clinical protocols.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
The Blood and Marrow Transplant Clinical Trials Network
(BMT CTN) was established in 2001 to conduct large, multi-
institutional clinical trials with the goal of improving the
outcomes of hematopoietic cell transplantation (HCT) for
patients facing life-threatening disorders. The BMT CTN al-
lows the HCT community to conduct prospective, collabo-
rative, clinical research within an infrastructure designed to
offer participation in HCT clinical trials to patients in all re-
gions of the United States. Nearly 18,000 HCTs are performed
in the United States annually and this increases by approxi-
mately 5% per year [1]. This growth reﬂects the utility of HCTedgments on page 6.
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ty for Blood and Marrow Transplantation.in treating both malignant and nonmalignant disease, a
higher donor availability, and treatment advances that allow
HCT to be performed in older and sicker patients. Although
HCT is a rapidly evolving ﬁeld, HCT clinical trials face unique
challenges, including the relatively small number of HCTs
performed at any single center, the diverse indications for
HCT, the complexities of the procedure and risks for multiple
post-transplantation complications. The BMT CTN was
established to address these challenges and execute multi-
center HCT trials with broad national participation. Well-
designed HCT trials beneﬁt from standardized criteria for
deﬁning diagnoses, treatment plans, and graft source
selection.
The development of clinical guidelines and standards
founded on evidence-based research is an important aspect
of directing and implementing clinical patient care. Over the
past decade, there have been signiﬁcant developments in
HLA-typing technologies and in the availability of outcome
data from large multicenter studies evaluating a growing
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vide guidance for consideration in development of clinical
trial protocols to ensure generalizability of the results to
standard of care treatment.
A recent review of current and completed clinical trials
within the BMT CTN illustrated signiﬁcant variability in the
donor and recipient HLA-matching criteria used in these
trials.*
Based upon available clinical research data, it was deter-
mined that future clinical studies would beneﬁt from the
utilization of consistent criteria regarding the most relevant
HLA and non-HLA factors to consider in the selection of
related and unrelated adult volunteer progenitor cell donors
or umbilical cord blood units. The BMT CTN has adopted the
following guidelines for HLA evaluation and donor/recipient
matching.
RELATED DONOR STEM CELL TRANSPLANTATIONS
Fully HLA-Matched Sibling
An HLA identical or fully HLA-matched sibling is consid-
ered the optimal and ﬁrst choice graft for allogeneic HCT. The
recipient, siblings, and parents (where available) should be
HLA-A and -B typed at intermediate or higher resolution and
HLA-DRB1 typed at high resolution by DNA-based methods
as a minimum requirement. Where possible, familial haplo-
types should be assigned to establish presumptive high-
resolution match identity between the donor and recipient
(additional HLA loci may be considered, eg, HLA-C and
-DQB1). The recipient and selected sibling donor should be a
6/6 match at HLA-A, -B, and -DRB1. In the absence of family
typing to establish familial haplotypes, high-resolution
typing by DNA-based methods should be performed and
the recipient and donor fully matched at HLA-A, -B, -C, and
-DRB1.
HLA-Mismatched Relative
Two thirds or more of all patients in the United States will
lack an HLA-matched sibling and must consider an alterna-
tive graft choice [2]. Clinical studies have shown partially
HLA-mismatched related (eg, 1 HLA antigen mismatched or
HLA haplo-identical) hematopoietic stem cell grafts can be a
suitable source of donor cells in some settings, thus
extending this treatmentmodality to patients who lack other
donors [3-5]. Mismatched related donors are assigned to
categories based on the level of HLA match.
One antigen mismatched related donor
The donor differs from the recipient by a single HLA an-
tigen (eg, sibling with a crossover). The recipient and donor
should be HLA-A, -B, -C typed at intermediate or higher
resolution and HLA-DRB1 typed at high resolution by DNA-
based methods as a minimum requirement. The recipient
and selected related donor should be a 7/8 match at HLA-A,
-B, -C and -DRB1.
Haplo-identical related donor
Parents, siblings, and other relatives sharing a single HLA
haplotype with the recipient are considered haplo-identical.
The recipient and the selected donor should be HLA-A, -B,
and -C typed at intermediate or higher resolution and HLA-
DRB1 typed at high resolution by DNA-based methods as a* BMT CTN clinical protocols can be accessed on the public BMT CTN
website at https://web.emmes.com/study/bmt2/index.html.minimum requirement. Where possible, familial haplotypes
should be assigned to establish haploidentity between the
donor and recipient. The recipient and related donor should
be  4/8 match at HLA-A, -B, -C, and -DRB1, with only 1
mismatch per locus. A signiﬁcant risk of graft failure exists in
the setting of HLA-mismatched related transplantation in
HLA-sensitized patients [6]. Patients should be screened for
the presence of antibodies and donors carrying an HLA target
should be avoided if possible. Data on recipient desensiti-
zation to reduce titers of donor speciﬁc antibodies are now
emerging, but further studies are needed to better reﬁne this
strategy.
UNRELATED DONOR STEM CELL TRANSPLANTATION
Viable alternatives to related donors are well-matched
unrelated donors and cord blood units. The development of
large international volunteer donor registries and cord blood
banks facilitate availability of a stem cell source for nearly all
patients without a suitable related donor [7].
Adult Unrelated Donor
Based on the ﬁndings of numerous large, contemporary
retrospective studies and comprehensive reviews, overall
survival is increased and transplantation-related mortality
reduced when recipients of unrelated donor hematopoietic
stem cell transplantations are evaluated andmatched at high
resolution for HLA-A, -B, -C, and -DRB1 (8/8 matched) [8-10].
When 8/8-matched adult volunteer donors are not available,
then a single HLA locus mismatched donor (7/8 matched)
can be considered with acceptable risks of transplantation-
related mortality [8]. HLA high-resolution match is deﬁned
as equivalent amino acid sequences (G group) in the antigen
recognition site (exon 2 and 3 for HLA class I and exon 2 for
HLA class II) of the molecule that binds peptide and interacts
with the T cell receptor [11]. The impact of variation outside
the antigen recognition site is not well characterized because
of limitations of the current typing methodologies and a lack
of clinical correlation studies [12,13].
When multiple equivalently matched unrelated donors
are available, the consideration of addition HLA loci and non-
HLA factors may be used to prioritize the ﬁnal donor selec-
tion. Testing of additional HLA loci (eg, HLA-DPB1, DQB1, and
DRB3/4/5) will assist in selecting donors with minimal mis-
matching at low expression loci [14] and T cell epitope
permissive HLA-DPB1 mismatches [15-17]. Additionally,
extended HLA testing can also support the selection of
appropriate donors in the context of HLA-sensitized patients
to avoid the potential risk of graft failure [18,19]. In the 7/
8-matched setting, donors can also be prioritized for
permissive HLA-C*03:03/03:04 mismatches [20] or host-
versus-graft only mismatches [21] to optimize outcomes.
Finally, based upon the ﬁndings of a recently reported Center
for International Blood and Marrow Transplant Research
retrospective study [22], centers may want to consider: (1)
younger unrelated donors, found to be associated with less
acute graft-versus-host disease and better overall survival,
and (2) ABO compatible donors, which were also associated
with better survival.
Umbilical Cord Blood
Umbilical cord blood transplantations expand access to
patients unable to ﬁnd a suitable unrelated adult donor due
to a traditionally lower threshold of HLA match [8,23]. The
recipient and cord blood units should, at a minimum, be
typed at HLA-A and -B at intermediate resolution (or higher)
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methods. The recipient and selected cord blood unit or
units, in the case of a multiple cord blood transplantation,
should be  4/6-HLA match at HLA-A, B (intermediate res-
olution), and -DRB1 (high resolution).
A recently published retrospective study [24] supports
the consideration of high-resolution matching at HLA-A, B, C,
and DRB1 to maximize graft success and minimize risks of
nonrelapse mortality. The study also found that the impact of
HLA matching was not offset by increasing cell dose beyond
the minimal recommended total nucleated cell dose of 
3 107/kg. Future clinical studies maywant to consider HLA-
A, -B, -C, and -DRB1 typing at high resolution by DNA-based
methods, with the recipient and selected cord blood unit
being a  6/8 HLA allele match at HLA-A, -B, -C, and -DRB1.
When multiple suitably matched, adequate cell dose cord
blood units are available, additional criteria may help guide
the ﬁnal cord blood unit selection(s). As with mismatched
unrelated donors, extended HLA testing can also support the
selection of appropriate cord blood units in the context of
HLA-sensitized patients to avoid the potential risk of graft
failure [25,26]. There is also evidence to suggest that
selecting a mismatched cord blood unit where the mismatch
involves a noninherited maternal antigen may improve sur-
vival [27,28].BMT CTN RECOMMENDATIONS
The minimum recommendations for donor/cord blood
and recipient HLA testing and matching (Table 1) represent
the consensus opinion of the BMT CTN Steering Committee,
with support and endorsement by the American Society of
Histocompatibility and Immunogenetics. The recommenda-
tions have been adopted for use in future BMT CTN clinicalTable 1
Recommendations for Donor HLA Assessment and Matching Categorization
for Allogeneic Stem Cell Transplantation Clinical Trial Protocol Development
Allogeneic
Transplantation
Donor and Recipient HLA Matching
Recommendation
Matched sibling 6/6 HLA match
HLA-A and -B (at intermediate or higher
resolution using DNA-based typing)
HLA-DRB1 (at high resolution using DNA-
based typing)
One antigen
mismatched
related
7/8 HLA match
HLA-A, -B, -C (at intermediate or higher
resolution using DNA-based typing)
HLA-DRB1 (at high resolution using DNA-
based typing)
Haploidentical
related
4/8 HLA match
HLA-A, -B, -C (at intermediate or higher
resolution using DNA-based typing)
HLA-DRB1 (at high resolution using
DN-based typing)
(fewer than 2 mismatches per locus)
8/8 Matched
unrelated
adult
8/8 HLA match
HLA-A, -B, -C, and -DRB1 (at high resolution
using DNA-based typing)
7/8 Unrelated
adult
7/8 HLA match
HLA-A, -B, -C, and -DRB1 (at high resolution
using DNA-based typing)
[7/8 donor available in most situations,
do not recommend  6/8]
Umbilical cord
blood
4/6 HLA match
HLA-A, -B (intermediate resolution or higher
using DNA-based typing) and -DRB1 (at high
resolution using DNA-based typing)trial development and will allow for generalization of donor/
recipient compatibility across protocols.ACKNOWLEDGMENTS
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